POS-320 EFFECTIVENESS AND SAFETY OF RIVAROXABAN VERSUS WARFARIN IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS WITH OBESITY, TYPE TWO DIABETES AND CKD
Sherzod AbdullaevRepublican Scientific and Practical Medical Center of Nephrology and Kidney Transplantation, Immunogenetics, Tashkent, UzbekistanRanokhon IgamberdievaTashkent pediatric medical institute, Internal medicine, Tashkent, Uzbekistan
ABI
Annotatsiya
We aimed to evaluate the clinical characteristics and outcomes of rivaroxaban and warfarin in patients with nonvalvular atrial fibrillation (NVAF) and concurrent obesity, type two diabetes (T2D) and chronic kidney disease (CKD)
Hali tarjima qilinmagan
Mavzular
Identifikatorlar
Iqtiboslar va manbalar
0 ta iqtibos0 ta foydalanilgan manba